GlobeNewsWire
29 Sept 2026, 21:39 UTC · 2h ago
Verdict
Headline takes no side. We score NVS −0.80 across two claims — strongly bearish.
−0.80strongly bearish
More negative than 84% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish · 1 new · 1 priced in
The global Phase III HARBOR study for del-desiran in people with myotonic dystrophy type 1 did not demonstrate statistically significant improvement versus placebo on its primary endpoint.
Priced inpress release dated September 8, 2026
More negative than 94% of claims this week
Pomerantz LLP is investigating whether Novartis and its officers engaged in securities fraud or unlawful business practices following the Phase III study results.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 68% of claims this week
Which stocks this story touches
More negative than 84% of ticker scores this week
The company is facing a class action investigation following a failed Phase III clinical trial and a significant drop in share price.
More negative than 72% of ticker scores this week
The company is the subject of an investigation into claims on behalf of investors.
More negative than 72% of ticker scores this week
The company is the subject of an investigation into claims on behalf of investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
2h ago
—
NVS hasn't traded since this ran. Last close $145.71 (Sep 29); the reaction starts at the next open.
NVS chart →
